Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Lillian L. Siu, Neeltje Steeghs, Tarek Meniawy, Markus Joerger, Jennifer L. Spratlin, Sylvie Rottey
Title Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.
URL http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.104#affiliationsContainer
Abstract Text Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 104-104

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
BMS-986156 BMS-986156 0 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
BMS-986156 BMS986156|BMS 986156 GITR Antibody 6 BMS-986156 is an activating monoclonal antibody that binds to TNFRSF18 (GITR, CD357), which leads to the activation of effector T cells and a decrease in T-regulatory cells, subsequently resulting in antitumor activity (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 104-104, PMID: 31697308).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References